EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study

S Bendaoud, S Nahon, L Beaugerie, J M Gornet, P Wils, A Amiot, L Peyrin-Biroulet, V Abitbol, X Hébuterne, R Altwegg, I Rosa, M Amil und 13 weitere

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.06.011 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von S Bendaoud und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hôpital Diaconesses-Croix Saint-Simon, Paris, France. Hauptthemen laut MEDLINE: Breast Feeding, Inflammatory Bowel Diseases, Pregnancy Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Association Francois Aupetit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anti-TNF are usually maintained during pregnancy in patients with inflammatory bowel disease (IBD) but safety is still a concern for them. AIMS: To provide data on management of anti-TNF agents during pregnancy, safety of live vaccines (BCG-MMR-rotavirus) and breastfeeding in newborns and dedicated information delivered to IBD women. METHODS: We performed an observational study in 25 centers from 2016 to 2018. We administered questionnaires to women with IBD receiving anti-TNF during pregnancy with newborn follow-up ≥ one year. RESULTS: Of 153 patients, 52 % maintained anti-TNF during the third trimester. Anti-TNF was shortly resumed in 79 % (58/73) after delivery. The rate of breastfeeding was 44 % (68/153) without any complication; 38 % of the mothers denied to breastfeed based on physician's advice. 26 % (34/129) of the newborns received live vaccines before 6 months-old (BCG:30 %; MMR:63 %; Rotavirus:8 %) and only 3 complications occurred (local BCGitis=1, fever=2). Information concerning anti-TNF during pregnancy/post-partum was delivered to 92 % of the patients, mainly by a gastroenterologist (97 %) who discussed with the obstetrician or the paediatrician in only 48 % and 25 %. CONCLUSION: In IBD patients, maintaining anti-TNF during pregnancy and breastfeeding is safe. Accidental live vaccines before 6 months did not lead to significant adverse events. The communication about these questions remains to improve.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast FeedingInflammatory Bowel DiseasesPregnancy ComplicationsHumansFemalePregnancyAdultInfant, NewbornSurveys and QuestionnairesTumor Necrosis Factor-alphaItalyMeasles-Mumps-Rubella VaccineTumor Necrosis Factor InhibitorsRotavirus Vaccines

Stichwörter der Autor:innen

Anti-TNF therapyBreastfeedingInflammatory bowel diseaseLive vaccinesPregnancy

Substanzen

Tumor Necrosis Factor-alphaMeasles-Mumps-Rubella VaccineTumor Necrosis Factor InhibitorsRotavirus Vaccines

Autor:innen und Institutionen

  • Department of Gastroenterology, Hôpital Diaconesses-Croix Saint-Simon, Paris, France.
  • Department of Gastroenterology, Montfermeil, France.
  • Department of Gastroenterology, Saint Antoine hospital, Paris, France.
  • Department of Gastroenterology, Saint Louis hospital, Paris, France.
  • Department of Gastroenterology, Claude Huriez hospital, University of Lille 2, Lille, France; Inserm, CHU Lille, U1286- INFINITE- Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille,…
  • Department of Gastroenterology, Kremlin Bicêtre Hospital, Kremlin-Bicêtre, France.

Förderung

  • Association Francois Aupetit

Zitieren

APA

Bendaoud, S., Nahon, S., Beaugerie, L., Gornet, J. M., Wils, P., Amiot, A., Peyrin-Biroulet, L., Abitbol, V., Hébuterne, X., Altwegg, R., Rosa, I., Amil, M., Heluwaert, F., Plastaras, L., Stefanescu, C., Quentin, V., Antoni, M., Bideau, K., Boualit, M., …, & Simon, M. (2024). Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.06.011

Vancouver

Bendaoud S, Nahon S, Beaugerie L, Gornet JM, Wils P, Amiot A, et al. Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.06.011

BibTeX
@article{Bendaoud2024,
  author = {Bendaoud, S and Nahon, S and Beaugerie, L and Gornet, J M and Wils, P and Amiot, A and Peyrin-Biroulet, L and Abitbol, V and Hébuterne, X and Altwegg, R and Rosa, I and Amil, M and Heluwaert, F and Plastaras, L and Stefanescu, C and Quentin, V and Antoni, M and Bideau, K and Boualit, M and Cuillerier, E and Locher, C and Skinazi, F and Boureille, A and Buisson, A and Simon, M},
  title = {Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.06.011}
}
Kostenlos starten →